ID   PCI-06A
AC   CVCL_C173
SY   PCI-6A; PCI6A; PCI-6T; PCI-6.1
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 990
DR   cancercelllines; CVCL_C173
DR   Cell_Model_Passport; SIDM00115
DR   Cosmic-CLP; 1240206
DR   DepMap; ACH-002298
DR   EGA; EGAS00001000978
DR   GDSC; 1240206
DR   GEO; GSM1670345
DR   PharmacoDB; PCI6A_1254_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54938652
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=2766286;
RX   PubMed=8084624;
RX   PubMed=14996750;
RX   PubMed=17312569;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Glu (c.50G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>T; ClinVar=VCV001264355; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.89%; Native American=0%; East Asian, North=1.02%; East Asian, South=0%; South Asian=0.59%; European, North=68.64%; European, South=28.85% (PubMed=30894373).
CC   Derived from site: In situ; Oral cavity, tonsil; UBERON=UBERON_0002372.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,13,14
ST   D16S539: 11,14
ST   D5S818: 11
ST   D7S820: 7,10
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C8183; Tonsillar squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C174 ! PCI-06B
SX   Male
AG   81Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 29
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=2766286;
RA   Heo D.S., Snyderman C.H., Gollin S.M., Pan S., Walker E., Deka R.,
RA   Barnes E.L., Johnson J.T., Herberman R.B., Whiteside T.L.;
RT   "Biology, cytogenetics, and sensitivity to immunological effector
RT   cells of new head and neck squamous cell carcinoma lines.";
RL   Cancer Res. 49:5167-5175(1989).
//
RX   PubMed=8084624; DOI=10.1177/01945998941113P105;
RA   Snyderman C.H., Klapan I., Milanovich M., Heo D.S., Wagner R.,
RA   Schwartz D.R., Johnson J.T., Whiteside T.L.;
RT   "Comparison of in vivo and in vitro prostaglandin E2 production by
RT   squamous cell carcinoma of the head and neck.";
RL   Otolaryngol. Head Neck Surg. 111:189-196(1994).
//
RX   PubMed=14996750; DOI=10.1158/0008-5472.CAN-03-2968;
RA   Wang J., Xi L.-Q., Hunt J.L., Gooding W., Whiteside T.L., Chen Z.,
RA   Godfrey T.E., Ferris R.L.;
RT   "Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in
RT   squamous cell carcinoma of the head and neck identifies a novel
RT   metastatic phenotype.";
RL   Cancer Res. 64:1861-1866(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//